Other Events ·
PRF Technologies reports $11.0M cash position and plans to start Phase 2 trial of OcuRing before year-end
PRFXPRF Technologies Ltd.
PRF Technologies reported preliminary consolidated cash, including short-term deposits, of approximately $11.0 million as of September 30, 2026, with total liabilities of roughly $2.5 million and an operating loss of $3.7 million for the nine months ended that date. The company raised about $10.5 million in gross proceeds through its equity line facility during this period. Its subsidiary LayerBio expects to begin enrolling patients in a U.S. multi-center Phase 2 clinical trial for OcuRing™-K before year-end. Additionally, PRF announced plans to establish GridFeed as a standalone subsidiary to pursue strategic transactions and evaluate opportunities in AI data center power optimization. PRF Technologies is a company focused on the reformulation of established therapeutics and the development of AI-driven energy optimization technologies.